{"groups":[{"description":"Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2)"},{"description":"Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"FG001","title":"Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2)"},{"description":"Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"FG002","title":"Dose Level 3 (Flavopiridol 50 mg/m2 + 50 mg/m2)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"19"},{"groupId":"FG002","numSubjects":"14"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"12"}],"type":"Patients Evaluable for Toxicity"},{"achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"12"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients with confirmed diagnosis of NHL (Non-Hodgkin's lymphoma) were accrued to one of the four cohorts defined by the World Health Organization criteria: indolent B-cell, mantle cell, intermediate-grade B-cell including transformed lymphoma and T-/NK-cell excluding primary cutaneous disease.","recruitmentDetails":"Patients were accrued to the study between April 2006 and September 2010."}